Antibody–Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/978-3-031-33602-7_1
Reference85 articles.
1. Al jarroudi O, Abda N, Brahmi S, Afqir S (2017) Triple negative breast cancer at the University Hospital Mohammed VI—Oujda. Asian Pac J Cancer Prevention : APJCP 18(1):195–200. https://doi.org/10.22034/APJCP.2017.18.1.195
2. Vidula N, Ellisen LW, Bardia A (2020) Novel agents for metastatic triple-negative breast cancer: finding the positive in the negative. J Natl Compr Cancer Netw: JNCCN 1–9. https://doi.org/10.6004/jnccn.2020.7600
3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767. https://doi.org/10.1172/JCI45014
4. Kim S-B, Dent R, Im S-A, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J (2017) LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 18(10):1360–1372. https://doi.org/10.1016/S1470-2045(17)30450-3
5. Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero J-M, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R et al (2020) Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol: Off J Am Soc Clin Oncol 38(5):423–433. https://doi.org/10.1200/JCO.19.00368
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Extracellular Vesicles in Breast Cancer: From Intercellular Communication to Therapeutic Opportunities;Pharmaceutics;2024-05-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3